Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 66, 10292-10301, November 1, 2006. doi: 10.1158/0008-5472.CAN-05-4414
© 2006 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ivshina, A. V.
Right arrow Articles by Miller, L. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ivshina, A. V.
Right arrow Articles by Miller, L. D.

Molecular Biology, Pathobiology, and Genetics

Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer

Anna V. Ivshina1, Joshy George1, Oleg Senko5, Benjamin Mow2, Thomas C. Putti3, Johanna Smeds6, Thomas Lindahl6, Yudi Pawitan7, Per Hall7, Hans Nordgren8, John E.L. Wong2,4, Edison T. Liu1, Jonas Bergh6, Vladimir A. Kuznetsov1 and Lance D. Miller1

1 Genome Institute of Singapore; 2 Department of Haematology-Oncology, National University Hospital; Departments of 3 Pathology and 4 Medicine, National University of Singapore, Singapore; 5 Russian Computer Center, Russian Academy of Sciences, Moscow, Russia; 6 Department of Oncology and Pathology, Radiumhemmet, Karolinska Institute and Hospital; 7 Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden; and 8 Department of Pathology, Akademiska sjukhuset, University of Uppsala, Uppsala, Sweden

Requests for reprints: Lance D. Miller, Genome Institute of Singapore, Genome Building 02-01, 60 Biopolis Street, Singapore 13872, Singapore. Phone: 65-6478-8100; Fax: 65-6478-9060; E-mail: MillerL{at}gis.a-star.edu.sg and Vladimir A. Kuznetsov, Genome Institute of Singapore, Genome Building 02-01, 60 Biopolis Street, Singapore 13872, Singapore. Phone: 65-6478-8198; Fax: 65-6478-9058; E-mail: kuznetsov{at}gis.a-star.edu.sg.

Histologic grading of breast cancer defines morphologic subtypes informative of metastatic potential, although not without considerable interobserver disagreement and clinical heterogeneity particularly among the moderately differentiated grade 2 (G2) tumors. We posited that a gene expression signature capable of discerning tumors of grade 1 (G1) and grade 3 (G3) histology might provide a more objective measure of grade with prognostic benefit for patients with G2 disease. To this end, we studied the expression profiles of 347 primary invasive breast tumors analyzed on Affymetrix microarrays. Using class prediction algorithms, we identified 264 robust grade-associated markers, six of which could accurately classify G1 and G3 tumors, and separate G2 tumors into two highly discriminant classes (termed G2a and G2b genetic grades) with patient survival outcomes highly similar to those with G1 and G3 histology, respectively. Statistical analysis of conventional clinical variables further distinguished G2a and G2b subtypes from each other, but also from histologic G1 and G3 tumors. In multivariate analyses, genetic grade was consistently found to be an independent prognostic indicator of disease recurrence comparable with that of lymph node status and tumor size. When incorporated into the Nottingham prognostic index, genetic grade enhanced detection of patients with less harmful tumors, likely to benefit little from adjuvant therapy. Our findings show that a genetic grade signature can improve prognosis and therapeutic planning for breast cancer patients, and support the view that low- and high-grade disease, as defined genetically, reflect independent pathobiological entities rather than a continuum of cancer progression. (Cancer Res 2006; 66(21): 10292-301)




This article has been cited by other articles:


Home page
JAMAHome page
C. R. Acharya and A. Potti
Documenting Biospecimen Conditions in Reports of Studies--Reply
JAMA, August 13, 2008; 300(6): 651 - 651.
[Full Text] [PDF]


Home page
JCOHome page
C. K. Anders, D. S. Hsu, G. Broadwater, C. R. Acharya, J. A. Foekens, Y. Zhang, Y. Wang, P. K. Marcom, J. R. Marks, P. G. Febbo, et al.
Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression
J. Clin. Oncol., July 10, 2008; 26(20): 3324 - 3330.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. A. Rakha, M. E. El-Sayed, A. H.S. Lee, C. W. Elston, M. J. Grainge, Z. Hodi, R. W. Blamey, and I. O. Ellis
Prognostic Significance of Nottingham Histologic Grade in Invasive Breast Carcinoma
J. Clin. Oncol., July 1, 2008; 26(19): 3153 - 3158.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
X.-J. Ma, R. Salunga, S. Dahiya, W. Wang, E. Carney, V. Durbecq, A. Harris, P. Goss, C. Sotiriou, M. Erlander, et al.
A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer
Clin. Cancer Res., May 1, 2008; 14(9): 2601 - 2608.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
N. P. S. Crawford, J. Alsarraj, L. Lukes, R. C. Walker, J. S. Officewala, H. H. Yang, M. P. Lee, K. Ozato, and K. W. Hunter
Bromodomain 4 activation predicts breast cancer survival
PNAS, April 29, 2008; 105(17): 6380 - 6385.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
C. R. Acharya, D. S. Hsu, C. K. Anders, A. Anguiano, K. H. Salter, K. S. Walters, R. C. Redman, S. A. Tuchman, C. A. Moylan, S. Mukherjee, et al.
Gene Expression Signatures, Clinicopathological Features, and Individualized Therapy in Breast Cancer
JAMA, April 2, 2008; 299(13): 1574 - 1587.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Finetti, N. Cervera, E. Charafe-Jauffret, C. Chabannon, C. Charpin, M. Chaffanet, J. Jacquemier, P. Viens, D. Birnbaum, and F. Bertucci
Sixteen-Kinase Gene Expression Identifies Luminal Breast Cancers with Poor Prognosis
Cancer Res., February 1, 2008; 68(3): 767 - 776.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Debled, G. MacGrogan, I. de Mascarel, V. Brouste, H. Bonnefoi, and L. Mauriac
Expression Profiling in Breast Carcinoma: New Insights on Old Prognostic Factors?
J. Clin. Oncol., September 20, 2007; 25(27): 4316 - 4317.
[Full Text] [PDF]


Home page
JCOHome page
S. Loi, B. Haibe-Kains, C. Desmedt, and C. Sotiriou
In Reply
J. Clin. Oncol., September 20, 2007; 25(27): 4317 - 4318.
[Full Text] [PDF]


Home page
NEJMHome page
F. Bertucci, N. Cervera, D. Birnbaum, K. Wennmalm, L. D. Miller, J. Bergh, W. A. Woodward, A. Lucci, M. Cristofanilli, the Advanced Research Center for Micrometastatic D, et al.
A Gene Signature in Breast Cancer
N. Engl. J. Med., May 3, 2007; 356(18): 1887 - 1888.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.